ProAssurance Corporation (PRA)

Groupe la Francaise acquired a new stake in shares of ProAssurance Corporation (NYSE: PRA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 214,228 shares of the insurance provider's stock, valued at approximately $4,891,000. Groupe la Francaise owned about 0.42% of ProAssurance

Shares of ProAssurance Corporation (NYSE: PRA - Get Free Report) have been assigned an average recommendation of "Reduce" from the six research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company. The average 12 month

PRA misses Q3 EPS estimates as weak Specialty P&C results and higher costs outweigh gains in investment income.

The headline numbers for ProAssurance (PRA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ProAssurance (PRA) came out with quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.34 per share a year ago.

BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported net income of $1.4 million, or $0.03 per diluted share, and operating income(1) of $7.9 million, or $0.15 per diluted share, for the three months ended September 30, 2025. For the nine months ended September 30, 2025, net income was $17.5 million, or $0.34 per diluted share, and operating income was $41.5 millio.

Despite higher catastrophe losses, HRTG, PRA, and HCI not only outperform the industry but also crush the Zacks S&P 500 composite and Finance sector.

STRASBOURG, France, Aug. 13, 2025 /PRNewswire/ -- Qaelon Medical, a pioneer in real-time surgical leak detection and constant-flow insufflation technologies, today welcomed two new members to its Data Advisory Board (DAB): Shanna Cotti, industry Chief Information Officer, and Robert D. Francis, President, Medical Professional Liability, ProAssurance Corporation. Robert and Shanna join existing DAB members Professor David Jayne and Assistant Professor Amin Madani announced last month. The multidisciplinary board will guide Qaelon's data strategy with an initial focus on two areas: "We are thrilled to welcome Shanna and Rob to Qaelon's Data Advisory Board," said Eran Shlomovitz, MD, FRCPC, FRCSC, FACS, Chief Medical Officer and Founder of Qaelon Medical. "Their deep expertise and insight will help ensure our technology is optimally deployed to save lives and reduce healthcare costs by establishing the first standardized, data-driven test methodology for surgical leak detection." Data-Driven Surgical Leak DetectionQaelon's proprietary leak detection system, the first to provide quantifiable, EMR-exportable leak assessments via a proprietary constant-flow insufflator, delivers objective insights in under 30 seconds. Validated in over 1,200 preclinical tests, it modernizes a century-old workflow, enabling surgeons to identify and address life-threatening leaks in real-time to reduce risks of sepsis, reoperation, or death. "We're bringing the standard for surgical leak testing into the digital age while expanding the ecosystem of the intelligent OR," said Liam Burns, CEO of Qaelon Medical. "With guidance from our Data Advisory Board, we're creating the first Objective Performance Indicator (OPI) for surgical leaks, which will enable AI-powered clinical decision-making support, while advancing a measurable, outcomes-focused standard of care." About Qaelon MedicalQaelon Medical is redefining leak detection in surgery. Its platform is the first and only system that combines real-time, AI-powered detection with precision insufflation, creating the foundation for intraoperative surgical intelligence. Headquartered in Strasbourg, France, Qaelon is backed by industry veterans, strategic partners like Caresyntax, and a global network of clinical innovators. For more information, visit www.qaelonmedical.com or contact [email protected].

PRA's Q2 earnings top estimates as lower expenses and higher investment income offset weaker premiums.

Although the revenue and EPS for ProAssurance (PRA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

ProAssurance (PRA) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.23 per share a year ago.

BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported net income of $21.9 million, or $0.42 per diluted share, and operating income(1) of $26.8 million, or $0.52 per diluted share, for the three months ended June 30, 2025. For the six months ended June 30, 2025, net income was $16.1 million, or $0.31 per diluted share, and operating income was $33.6 million, or $0.

NAPA, Calif. & BIRMINGHAM, Ala.--(BUSINESS WIRE)--The Doctors Company, the nation's largest physician-owned medical malpractice insurer, and ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical liability, products liability for medical technology and life sciences, and workers' compensation insurance, announced today that on July 2, 2025, the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Sc.

BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE: PRA) today announced that stockholders have voted overwhelmingly to approve its proposed acquisition by The Doctors Company. More than 99% of shares voted (including abstentions) were in favor of the proposal to approve the acquisition agreement. The transaction remains subject to the receipt of regulatory approvals and other customary closing conditions and is expected to close in the first half of 2026. Required regulatory app.

ProAssurance (PRA) reported earnings 30 days ago. What's next for the stock?